Aruc, no, a deal could be easily signed simply based on condition of efficacy, for an initial period.
It's very different in Japan where phase III trials are not needed for commercialisation. Many clients will want to get in early before anyone else does, with a favourable deal. This actually could have a downside for RGS only in that if the product does turn out to be a real winner, then they could uniwttingly undersell the value.
Ann: Enrolment complete and positive safety in Progenza trial-RGS.AX, page-4
Add CMB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.020(4.76%) |
Mkt cap ! $4.832M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.0¢ | 40.0¢ | $2.792K | 6.87K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7117 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 1910 | 1 |
View Market Depth
| Last trade - 14.13pm 29/07/2024 (20 minute delay) ? |
| CMB (ASX) Chart |